Exelixis ((EXEL)), Novartis AG ((NVS)), Bristol-Myers Squibb Company ((BMY)), Clovis Oncology Inc ((CLVSQ)), DEL_Novartis (0QM7) ((DEL_0QM7)), DEL_Novartis Inc ((DEL_0QLR)), Novartis ((CH:NOVN)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The Pan-Tumor Rollover Study, officially titled ‘Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies,’ aims to assess the long-term safety of nivolumab monotherapy and its combinations in various cancer types. This study is significant as it evaluates the extended use of these therapies, potentially impacting treatment protocols for cancer patients.
The study tests several interventions, primarily focusing on nivolumab, both as a monotherapy and in combination with other drugs like ipilimumab, cabozantinib, and relatlimab. These interventions aim to enhance cancer treatment efficacy and patient outcomes.
Designed as an interventional, non-randomized, parallel assignment study, it focuses on treatment as its primary purpose. The study does not employ masking, allowing for open observation of treatment effects.
The study began on August 9, 2019, with its primary completion and estimated completion dates yet to be determined. The latest update was submitted on July 7, 2025, indicating ongoing progress and adjustments.
This study update may positively influence the stock performance of involved companies like Bristol-Myers Squibb, Exelixis, and Novartis, as successful outcomes could lead to expanded market opportunities and increased investor confidence. The involvement of multiple industry players highlights the competitive landscape in cancer treatment innovations.
The study is ongoing, with further details available on the ClinicalTrials portal.